Vertex creates new possibilities in medicine to cure diseases and improve people's lives.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $163M
Founded date: 2014
Investors 4
| Date | Name | Website |
| - | T1D Fund | t1dfund.or... |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | 6 Dimensio... | 6dimension... |
| - | Eight Road... | eightroads... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 30.11.2017 | Series B | $114M | - |
| 12.09.2016 | Grant | $5M | - |
| 24.03.2015 | Series A | $44M | MPM Capita... |
Mentions in press and media 19
| Date | Title | Description |
| 25.06.2024 | Breakthrough T1D-Funded Research Featured at American Diabetes Association 84th Scientific Sessions | NEW YORK, June 25, 2024 /PRNewswire/ -- Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, gathered with researchers, diabetes professionals, and other leaders in T1D at the America... |
| 03.09.2019 | Vertex buys developer of preclinical cell therapy for Type 1 diabetes for $950M | Type 1 diabetes is an autoimmune disease that results from destruction of the insulin-producing beta cells in the endocrine pancreatic islets of Langerhans cells. A commentary published in May in the journal Diabetes by University of Pennsy... |
| 30.11.2017 | Semma Therapeutics Raises $114 Million Series B Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Semma Therapeutics, a biotechnology company focused on the development of novel regenerative medicines, announced today the successful completion of a highly oversubscribed $114 million Series B financing.... |
| 30.11.2017 | Semma Therapeutics Raises $114m for Novel Diabetes Treatment | - |
| 30.11.2017 | Semma Therapeutics Raises $114M in Series B Financing | Semma Therapeutics, a Cambridge, MA-based biotechnology company focused on the development of novel regenerative medicines, completed a $114m Series B financing. The round was co-led by Eight Roads Ventures and Cowen Healthcare Investments ... |
| 30.11.2017 | Semma scoops $114M to trial curative diabetes cell therapy | Semma Therapeutics has raised $114 million to take a potentially-curative Type 1 diabetes cell therapy through clinical proof of concept. The round positions Semma to start learning whether its insulin-producing cells can control blood suga... |
| 30.11.2017 | Term Sheet — Thursday, November 30 | A WILD WEDNESDAY Good morning, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop Here’s a quick summary of what’s been going on: Bitcoin blew past the $9,000 per coin mark on Sunday. Then, all hell broke loo... |
| 29.03.2017 | Gore joins ViaCyte’s quest for a functional type 1 diabetes cure | On Wednesday, the San Diego, California-based company announced a new partner; W. L. Gore & Associates, the multi-billion dollar manufacturer of medical and non-medical fabrics and devices, including the iconic GORE-TEX. If Gore can con... |
| 23.03.2017 | Semma Therapeutics Raises Additional Funding | Semma Therapeutics, a Cambridge, Massachusetts-based biopharmaceutical company, raised an undisclosed amount of funding. JDRF T1D Fund, a venture philanthropy fund devoted to finding and funding the best early-stage T1D commercial opportuni... |
| 23.03.2017 | Term Sheet — Thursday, March 23 | BREATHE Term Sheet readers may remember a time several years ago (when I was merely filling in as your daily columnist), we analyzed how hard it would be for an investor to short the startup market. We concluded, in short: It’s really hard.... |
Show more